Sarepta Therapeutics has halted shipments of its gene therapy Elevidys for Duchenne muscular dystrophy in older, non-ambulatory patients following a second reported death linked to acute liver injury. The therapy, initially approved under accelerated pathways for younger patients, faces safety concerns prompting the company to pause a study in the older cohort and seek expert advice on enhanced immunosuppressive protocols. The FDA is involved in evaluating potential modifications to the therapy’s use.